Download PDF
Klin Monbl Augenheilkd 2022; 239(05): 676-685
DOI: 10.1055/a-1686-5158
Übersicht

Uveitis bei juveniler idiopathischer Arthritis – leitliniengerechte Diagnostik und Therapie anhand von Kasuistiken

Article in several languages: deutsch | English
Arnd Heiligenhaus
1   Augenzentrum am St. Franziskus Hospital, Münster, Deutschland
,
Christoph Deuter
2   Department für Augenheilkunde, Universitätsklinikum Tübingen, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Zielsetzung Darstellung der aktuellen deutschsprachigen interdisziplinären Leitlinie zur Diagnostik und Therapie der JIA-assoziierten Uveitis (JIA: juvenile idiopathische Arthritis) anhand von Kasuistiken.

Material und Methoden Leitlinie der Deutschen Ophthalmologischen Gesellschaft, der Gesellschaft für Kinder- und Jugendrheumatologie, der Deutschen Gesellschaft für Rheumatologie, des Berufsverbandes der Augenärzte Deutschlands unter Beteiligung von Patientenvertretern. Die unlängst publizierte Primärliteratur wurde kritisch bewertet hinsichtlich Evidenz und Empfehlungen; methodisch wurden Konsensfindung mittels Delphi-Runden und eine externe Begutachtung einbezogen. Die Ergebnisse werden anhand von typischen Fallbeispielen erläutert.

Ergebnisse Bei JIA-Erstdiagnose sollten regelmäßige augenärztliche Kontrollen erfolgen mit dem Ziel, dass die Uveitis vor Manifestation irreversibler Folgeschäden diagnostiziert wird. Entsprechend dem individuellen Schweregrad der Uveitis kann eine qualitativ hochwertige Versorgung der Patienten erzielt werden. Zur antientzündlichen Therapie finden aktuell Kortikosteroide, konventionell synthetische (cs) und biologische (b) und andere Disease-modifying anti-rheumatic Drugs (DMARDs) Verwendung.

Schlussfolgerungen Frühzeitige Diagnose und aktuelle leitliniengerechte Therapie können die Langzeitprognose der JIA-assoziierten Uveitis wesentlich verbessern.

Schlüsselwörter

Diagnostik - juvenile idiopathische Arthritis - Therapie - Uveitis


Publication History

Received: 03 November 2021

Accepted: 13 December 2021

Article published online:
23 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Heiligenhaus A, Niewerth M, Ganser G. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015-1019
    CrossrefPubMedGoogle Scholar
  • 2 Kotaniemi K, Kautiainen H, Karma A. et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071-2075
    CrossrefPubMedGoogle Scholar
  • 3 Walscheid K, Glandorf K, Rothaus K. et al. Enthesitis-related arthritis: prevalence and complications of associated uveitis in children and adolescents from a population-based nationwide study in Germany. J Rheumatol 2021; 48: 262-269
    CrossrefPubMedGoogle Scholar
  • 4 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516
    CrossrefPubMedGoogle Scholar
  • 5 De Boer J, Steijaert A, van den Bor R. et al. Development of macular edema and impact and visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67-73
    CrossrefPubMedGoogle Scholar
  • 6 Böhm MR, Tappeiner C, Breitbach MA. et al. Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol 2017; 173: 45-55
    CrossrefPubMedGoogle Scholar
  • 7 Thorne JE, Woreta FA, Dunn JP. et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436-1441
    CrossrefPubMedGoogle Scholar
  • 8 Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485
    CrossrefPubMedGoogle Scholar
  • 9 De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884
    CrossrefPubMedGoogle Scholar
  • 10 Tappeiner C, Klotsche J, Schenck S. et al. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-944
    PubMedGoogle Scholar
  • 11 Heiligenhaus A, Minden K, Tappeiner C. et al. Update of the evidence-based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 2019; 49: 43-55
    CrossrefPubMedGoogle Scholar
  • 12 Heiligenhaus A, Klotsche J, Niewerth M. et al. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther 2020; 22: 81
    CrossrefPubMedGoogle Scholar
  • 13 Kothari S, Foster CS, Pistilli M. et al. The risk of intraocular pressure elevation in pediatric non-infectious uveitis. Ophthalmology 2015; 122: 1987-2001
    CrossrefPubMedGoogle Scholar
  • 14 Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365
    PubMedGoogle Scholar
  • 15 Heiligenhaus A, Mingels A, Heinz C. et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748
    CrossrefPubMedGoogle Scholar
  • 16 Samson CM, Waheed N, Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139
    CrossrefPubMedGoogle Scholar
  • 17 Kostik MM, Gaidar EV, Hynnes AY. et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol 2016; 34: 714-718
    PubMedGoogle Scholar
  • 18 Papadopoulou C, Kostik M, Böhm M. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-884
    CrossrefPubMedGoogle Scholar
  • 19 Tappeiner C, Schenck S, Niewerth M. et al. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res 2016; 68: 46-54
    CrossrefPubMedGoogle Scholar
  • 20 Lerman MA, Burnham JM, Chang PY. et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013; 40: 1394-1403
    CrossrefPubMedGoogle Scholar
  • 21 Acharya N, Patel S, Homayounfar G. et al. Relapse of juvenile idiopathic arthritis associated uveitis after discontinuation of immunomodulatory therapy. Ocul Immunol Inflamm 2019; 27: 686-692
    CrossrefPubMedGoogle Scholar
  • 22 Lerman MA, Lewen MD, Kempen JH. et al. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200
    CrossrefPubMedGoogle Scholar
  • 23 Horton S, Jones AP, Guly CM. et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol 2019; 207: 170-179
    CrossrefPubMedGoogle Scholar
  • 24 Simonini G, Druce K, Cimaz R. et al. Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66: 1073-1084
    CrossrefPubMedGoogle Scholar
  • 25 Vallet H, Seve P, Biard L. et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 2016; 68: 1522-1530
    CrossrefPubMedGoogle Scholar
  • 26 Cordero-Coma M, Calvo-Rio V, Adan A. et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm 2014; 2014: 717598
    CrossrefPubMedGoogle Scholar
  • 27 Miserocchi E, Modorati G, Pontikaki I. et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90-95
    CrossrefPubMedGoogle Scholar
  • 28 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637-1646
    CrossrefPubMedGoogle Scholar
  • 29 Tynjälä P, Lindahl P, Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550
    CrossrefPubMedGoogle Scholar
  • 30 Saurenmann RK, Levin AV, Feldman BM. et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833-836
    CrossrefPubMedGoogle Scholar
  • 31 Scrivo R, Spadaro A, Spinelli FR. et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-1556
    CrossrefPubMedGoogle Scholar
  • 32 Calvo-Rio V, Santos-Gomez M, Calvo I. et al. Anti-IL-6R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy. A multicenter study of 25 patients. Arthritis Rheumatol 2016; 69: 668-675
    CrossrefPubMedGoogle Scholar
  • 33 Tappeiner C, Mesquida M, Adan A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43: 2183-2188
    CrossrefPubMedGoogle Scholar
  • 34 Ramanan AV, Dick AD, Guly C. et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol 2020; 2: e135-e141
    CrossrefPubMedGoogle Scholar
  • 35 Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis – a case report. J Rheumatol 2008; 35: 1897-1898
    PubMedGoogle Scholar
  • 36 Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Arthritis Care Res 2011; 63: 307-310
    CrossrefPubMedGoogle Scholar
  • 37 Tappeiner C, Miserocchi E, Bodaghi B. et al. Abatacept in the treatment of severe, longstanding and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706-711
    CrossrefPubMedGoogle Scholar
  • 38 Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocular Immunol Inflamm 2019; 27: 1232-1234
    CrossrefPubMedGoogle Scholar
  • 39 Miserocchi E, Giuffre C, Cornalba M. et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851
    CrossrefPubMedGoogle Scholar
  • 40 Heiligenhaus A, Miserocchi E, Heinz C. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390-1394
    CrossrefPubMedGoogle Scholar
  • 41 Miserocchi E, Pontikaki I, Modorati G. et al. Rituximab for uveitis. Ophthalmology 2011; 118: 223-224
    CrossrefPubMedGoogle Scholar
  • 42 Miserocchi E, Modorati G, Berchicci L. et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016; 100: 782-786
    CrossrefPubMedGoogle Scholar
  • 43 Kalinina Ayuso V, van de Winkel EL, Rothova A. et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-222
    CrossrefPubMedGoogle Scholar